Company Overview and News

2
Top 20 Gold Stocks to Buy Despite Irrational Markets

18h investorplace
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.

 
KGC / Kinross Gold Corp. F-X

2018-05-21 sec.gov
U.S. SECURITIES AND EXCHANGE COMMISSION

 
KGC / Kinross Gold Corp. F-10

2018-05-21 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS

 
Is a Rebound in the Cards for Gold?

2018-05-21 marketrealist
After the massive slump in gold prices as US Treasury yields rose, the trading range for gold seems to have corrected lower. On Thursday, May 17, gold traded in the narrow range of $1,288 to $1,291.3 an ounce and finally closed at $1,288.2 an ounce, about 0.16% lower than the previous trading day. The relative strength index for gold has also fallen considerably to 28.2, which suggests that there could soon be a revival in the price of gold.

1
KGC / Kinross Gold Corp. FORM 6-K (Current Report of Foreign Issuer)

2018-05-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

 
Qiwi stock price target raised to $25 vs. $23 at JPMorgan

2018-05-18 marketwatch
It seems to be a wise decision for investors to drop Qiwi plc (QIWI) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.

 
Avidian Gold Announces C$5 Million Brokered Private Placement

2018-05-17 globenewswire
TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- Avidian Gold Corp. (“Avidian” or the “Company”) (TSX-V:AVG) is pleased to announce that it has appointed a syndicate of agents led by Red Cloud Klondike Strike Inc. and including PI Financial Corp., Canaccord Genuity Corp. and Mackie Research Capital Corp. (collectively, the “Agents”), to sell by way of private placement, units (the “Units”) of the Company for gross proceeds of up to C$5,000,000 (the “Offering”).

 
How the Dollar’s Surge Affected Precious Metals

2018-05-17 marketrealist
One of the most crucial factors causing a slump in the price of precious metals is the revival of the US dollar. The DXY, which prices the dollar against a basket of six major world currencies, rose 0.68% on May 15. The DXY gained 3.8% over the last month. During the same timeframe, gold fell 4.2%.

 
Brazil Minerals, Inc. Strikes Gold in the Paracatu Project

2018-05-16 globenewswire
PASADENA, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Brazil Minerals, Inc. (OTC:BMIX) (the "Company" or "Brazil Minerals") announced today that its subsidiary, Jupiter Gold Corporation (“Jupiter Gold”), is advancing the initial drilling campaign of its Paracatu Project and already struck gold in multiple holes drilled. Gold particles were obtained and confirmed in pan concentrates in samples taken.

2
Kinross Gold - Mauritania Spoiled The Company's Outstanding Quarter

2018-05-14 seekingalpha
Revenue for the fourth quarter was $897.2 million, up 12.7% from the year-ago quarter and 10.7% sequentially. Net earnings of $106.1 million, or $0.09 per share.

 
Ivanhoe Mines: A Deeply Undervalued Mining Giant In The Making

2018-05-11 seekingalpha
Ivanhoe holds three pre-production, world-class mines in Africa, i.e., Platreef for precious metals, Kipushi for zinc and copper, and Kamoa-Kakula for copper.

 
A Quick Look at the Technicals of the 4 Precious Metals

2018-05-10 marketrealist
Gold’s price dipped 0.13% to $1,312.8 per ounce on May 9. The fall in gold was extended for a number of reasons, including a decrease in overall volatility and rising US Treasury rates. We’ll discuss these factors at length in the next few articles.

2
Geopolitical Concerns Overwhelm Kinross Gold, Stock Plunges 11%

2018-05-10 marketrealist
Yesterday, Kinross Gold (KGC) recorded its worst one-day loss since 2014. While the stock plunged ~15% at one point, it settled ~11% lower at the end of the day. As we reported yesterday, the company’s 1Q18 earnings and revenues beat market expectations. Higher margins and a decline in depreciation, depletion, and amortization drove its headline earnings up 435% year-over-year (or YoY). That rise, however, sounded like the end of good news for the stock.

1
KGC / Kinross Gold Corp. FORM 6-K (Current Report of Foreign Issuer)

2018-05-10 sec.gov
SECURITIES AND EXCHANGE COMMISSION

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 496902404